Cancer Vaccine Market Size To Reach $23.31 Billion By 2033

January 2026 | Report Format: Electronic (PDF)

Cancer Vaccine Market Growth & Trends

The global cancer vaccine market size is expected to reach USD 23.31 billion by 2033, registering a CAGR of 11.30% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer among the population. According to the WHO, it is a leading cause of death globally, which accounted for 10 million deaths in 2020, with prostate, lung, breast, colon, skin, and stomach cancers being the most common types causing one in every six deaths worldwide. A rise in the number of cases can be majorly attributed to various factors, such as the rising geriatric population and changing prevalence of certain causes of cancer associated with economic & social development. This is particularly seen in emerging economies, wherein a general shift is observed in terms of cancers associated with poverty, which is a contrast to developed economies, wherein cases have increasingly been associated with lifestyle disorders.

According to the WHO, obesity, certain types of infections, and exposure to radiation are major factors associated with an increase in the number of cases. Moreover, the demand for vaccines is significantly increasing worldwide owing to technological advancements in the field of prevention. FDA support for developing biomarkers & mass cytometry; launch of various flow cytometry reagents for drug discovery & diagnosis; technologically advanced miniaturized devices, facilitating portability & precision; development of cell- & bead-based flow cytometry techniques are major factors boosting the market growth. Various programs to increase awareness about cancer by organizations are key factors responsible for the increased demand for innovative vaccines worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, CDC, WHO, the U.S. Preventive Services Task Force, and others for increasing screening of cervical cancer are major factors expected to augment the market growth during the forecast period.

Furthermore, key players involved in developing and formulating various vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the industry. Moreover, several players are involved in the development of novel vaccines to meet the rising demand for prevention of the condition. For instance, in February 2023, BioNTech announced plans to proceed with clinical trials for its vaccine from September 2023, which is expected to be launched in the market before 2030. In March 2023, Researchers at Cleveland Clinic announced the next step toward the launch of a vaccine for the prevention of triple-negative breast cancer, which is one of the most lethal forms of the condition.

key Request a free sample copy or view report summary: Cancer Vaccine Market Report

Cancer Vaccine Market Report Highlights

The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option.
Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited.
The Cancer Vaccine industry is marked by high levels of innovation, driven by breakthroughs in mRNA platforms, neoantigen targeting and personalized immunotherapy that tailor vaccines to individual tumor profiles.
The preventive Cancer Vaccine segment led the market with the largest revenue share of 52.14% in 2025, driven by strong public health policies, increasing adoption of HPV immunization into national schedules, and growing evidence that broad vaccination reduces future cancer burdens, strengthening buy-in from governments and healthcare payers.
The cervical cancer segment led the market with the largest revenue share of 30.74% in 2025, driven by expanded access initiatives, stronger policy support for HPV vaccination, and growing evidence that broad immunization significantly reduces disease burden and downstream treatment costs
The recombinant Cancer Vaccine segment led the market with the largest revenue share of 56.33% in 2025, driven by widespread clinical success, established manufacturing platforms, and strong integration of recombinant technologies into preventive and therapeutic vaccine design, appealing to public and private buyers alike
North America dominated the global Cancer Vaccine market with the largest revenue share of 35.47% in 2025, due to an advanced healthcare system and strong research and development focus from major biopharmaceutical companies